A Discrete Choice Experiment of Clinician Preferences Among Attributes of Approved Janus Kinase Inhibitors for Alopecia Areata.
Scalp hair regrowth was the most important attribute driving clinicians' janus kinase inhibitor choice.
A Discrete Choice Experiment of Clinician Preferences Among Attributes of Approved Janus Kinase Inhibitors for Alopecia Areata.
As the treatment landscape for alopecia areata (areata) expands, it is crucial to understand how treatment properties impact clinician decision-making.
The objective of the study was to understand how clinicians treating areata make decisions and evaluate the relative importance (relative importance) of treatment attributes.
An online discrete choice experiment (discrete choice experiment) was conducted among clinicians treating areata recruited through M3 Global Research's US panel from February to March 2024.
hair regrowth mattered most, driving over half of clinicians' treatment choice
Of the 249 screened clinicians, 155 were eligible for analysis (129 dermatologists, 15 physician assistants, and 11 nurse practitioners).
Clinicians were predominantly White (75.5%) and male (57.4%), with a mean age of 47.3 years.
Approximately 50% of the clinicians had been practicing for over 15 years, and the majority were in office-based practices (82%), seeing a mean of 38.8 patients with areata per month.
For the blinded treatment profiles, drug profile C was most preferred (72.2%) and drug profile B was least preferred (81.9%).
Our study demonstrated that, regarding janus kinase inhibitor treatment of areata, clinicians preferred options with higher efficacy and shorter time to onset regardless of once-daily or twice-daily dosing.